Pharmaceutical - Johnson & Johnson

Filter

Current filters:

Johnson & Johnson

Popular Filters

101 to 125 of 261 results

Pharmacyclics and Janssen gain third FDA "Breakthrough" designation for ibrutinib; new Ph II data

09-04-2013

Pharmacyclics (Nasdaq: PCYC) saw its shares gain 4.5% to $78.96 in early trading Monday, after it revealed…

ibrutinibJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

Xarelto and Eliquis set to displace current therapies in DVT/PE

28-03-2013

Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

Study shows additional role for abiraterone in blocking tumor growth in CRPC

17-03-2013

As part of a European Union-supported IMI-PREDECT consortium (http://www.predect.eu), a Dutch study showed…

abirateroneJanssenJohnson & JohnsonOncologyPharmaceuticalResearchZytiga

Bayer and J&J initiate new trials to expand use of Xarelto

08-03-2013

German drug major Bayer (BAYN: DE) and partner Janssen, a subsidiary of US health care giant Johnson…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

Australia to subsidize groundbreaking hepatitis C drugs under PBS

19-02-2013

The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

US FDA grants "breakthrough" status for Janssen and Pharmacyclics ibrutinib

14-02-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, says that…

BiotechnologyibrutinibJohnson & JohnsonNorth AmericaOncologyPharmaceuticalPharmacyclicsRegulationResearch

Bayer and Janssen link with Portola for Xarelto antidote

06-02-2013

Germany's Bayer (BAYN: DE) and Janssen Pharmaceuticals, a part of US health care giant Johnson & Johnson…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalPortola PharmaceuticalsPRT4445Research

EU Commission sends antitrust complaint to Johnson & Johnson and Novartis

01-02-2013

The European Commission has informed US health care giant Johnson & Johnson (NYSE: JNJ) and Swiss drug…

DuragesicEuropefentanylGenericsJanssen-CilagJohnson & JohnsonLegalMarkets & MarketingNeurologicalNovartisPatentsPharmaceuticalSandoz

European Commission enforcement action in pharmaceutical sector following sector inquiry

31-01-2013

Following its competition inquiry into the pharmaceutical sector of 2008/2009, the European Commission…

DuragesicEuropeGenericsJohnson & JohnsonLundbeckMarkets & MarketingPatentsPharmaceuticalServier

Johnson & Johnson 4th-qtr sales miss expectations and guidance disappoints

23-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) yesterday posted fourth-quarter and full-year 2012…

FinancialJohnson & JohnsonPharmaceutical

Expanded indication for Janssen's Zytiga cleared in EU

14-01-2013

US health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen-Cilag International said Friday…

EuropeJanssen-CilagJohnson & JohnsonOncologyPharmaceuticalRegulationZytiga

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11-01-2013

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday…

canagliflozinDiabetesInvokanaJanssenJohnson & JohnsonMitsubishi TanabeNorth AmericaPharmaceuticalRegulation

Licensing deals for Philogen with Pfizer and GlycoVaxyn with Janssen

07-01-2013

Privately held Italian biopharma firm Philogen SpA (Siena, Italy) has granted global drugs behemoth Pfizer…

BiotechnologyDekavilGlycoVaxynInflammatory diseasesJanssenJohnson & JohnsonLicensingPfizerPharmaceuticalPhilogenVaccines

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Janssen's TB drug Sirturo gains US FDA approval

02-01-2013

The US Food and Drug Administration has granted accelerated approval for US health care major Johnson…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationSirturo

Public Citizen urges FDA to reject accelerated approval for Janssen's bedaquiline

27-12-2012

The US Food and Drug Administration should not approve the anti-tuberculosis drug bedaquiline from Janssen,…

Antibiotics and Infectious diseasesbedaquilineJohnson & JohnsonNorth AmericaPharmaceuticalRegulation

101 to 125 of 261 results

Back to top